| dc.contributor.author | Martín-Montero, Adrián | |
| dc.contributor.author | Gutiérrez-Tobal, Gonzalo C | |
| dc.contributor.author | Kheirandish-Gozal, Leila | |
| dc.contributor.author | Vaquerizo-Villar, Fernando | |
| dc.contributor.author | Álvarez, Daniel | |
| dc.contributor.author | del Campo, Félix | |
| dc.contributor.author | Gozal, David | |
| dc.contributor.author | Hornero, Roberto | |
| dc.date.accessioned | 2026-01-16T13:04:00Z | |
| dc.date.available | 2026-01-16T13:04:00Z | |
| dc.date.issued | 2022-02 | |
| dc.identifier.citation | Sleep, Mayo 2025, vo. 15, p.17574 | es |
| dc.identifier.issn | 0161-8105 | es |
| dc.identifier.uri | https://uvadoc.uva.es/handle/10324/81686 | |
| dc.description | Producción Científica | es |
| dc.description.abstract | Abstract
Study Objectives
Pediatric obstructive sleep apnea (OSA) affects cardiac autonomic regulation, altering heart rate variability (HRV). Although changes in classical HRV parameters occur after OSA treatment, they have not been evaluated as reporters of OSA resolution. Specific frequency bands (named BW1, BW2, and BWRes) have been recently identified in OSA. We hypothesized that changes with treatment in these spectral bands can reliably identify changes in OSA severity and reflect OSA resolution.
Methods
Four hundred and four OSA children (5–9.9 years) from the prospective Childhood Adenotonsillectomy Trial were included; 206 underwent early adenotonsillectomy (eAT), while 198 underwent watchful waiting with supportive care (WWSC). HRV changes from baseline to follow-up were computed for classical and OSA-related frequency bands. Causal mediation analysis was conducted to evaluate how treatment influences HRV through mediators such as OSA resolution and changes in disease severity. Disease resolution was initially assessed by considering only obstructive events, and was followed by adding central apneas to the analyses.
Results
Treatment, regardless of eAT or WWSC, affects HRV activity, mainly in the specific frequency band BW2 (0.028–0.074 Hz). Furthermore, only changes in BW2 were specifically attributable to all OSA resolution mediators. HRV activity in BW2 also showed statistically significant differences between resolved and non-resolved OSA.
Conclusions
OSA treatment affects HRV activity in terms of change in severity and disease resolution, especially in OSA-related BW2 frequency band. This band allowed to differentiate HRV activity between children with and without resolution, so we propose BW2 as potential biomarker of pediatric OSA resolution. | es |
| dc.format.mimetype | application/pdf | es |
| dc.language.iso | spa | es |
| dc.publisher | Oxford University Press | es |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
| dc.title | Heart rate variability as a potential biomarker of pediatric obstructive sleep apnea resolution | es |
| dc.type | info:eu-repo/semantics/article | es |
| dc.rights.holder | © Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society. | es |
| dc.identifier.doi | 10.1093/sleep/zsab214 | es |
| dc.relation.publisherversion | https://academic.oup.com/sleep/article/45/2/zsab214/6366352?login=true | es |
| dc.identifier.publicationissue | 2 | es |
| dc.identifier.publicationtitle | Sleep | es |
| dc.identifier.publicationvolume | 45 | es |
| dc.peerreviewed | SI | es |
| dc.description.project | This work was supported by “Ministerio de Ciencia, Innovación y Universidades—Agencia Estatal de Investigación” and “European Regional Development Fund (FEDER)” under projects DPI2017-84280-R and RTC-2017-6516-1, by “European Commission” and “FEDER” under project “Análisis y correlación entre la epigenética y la actividad cerebral para evaluar el riesgo de migraña crónica y episódica en mujeres” (“Cooperation Programme Interreg V-A Spain-Portugal POCTEP 2014–2020”), and by “CIBER en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)” through “Instituto de Salud Carlos III” co-funded with FEDER funds, as well as under the project SleepyHeart from 2020 valorization call. A. Martín-Montero was in receipt of a “Ayudas para contratos predoctorales para la Formación de Doctores” grant from the Ministerio de Ciencia, Innovación y Universidades (PRE2018-085219). F. Vaquerizo-Villar was in receipt of a “Ayuda para contratos predoctorales para la Formación de Profesorado Universitario (FPU)” grant from the Ministerio de Educación, Cultura y Deporte (FPU16/02938). Daniel Álvarez was supported by a “Ramón y Cajal” grant (RYC2019-028566-I) by the “Ministerio de Ciencia e Innovación—Agencia Estatal de Investigación” co-funded by ESF. L. Kheirandish-Gozal and D. Gozal were supported by National Institutes of Health (NIH) grant HL130984, the Leda J. Sears Foundation, and by a Tier 2 grant from the University of Missouri. D. Gozal is also supported by NIH grants HL140548, and AG061824. | es |
| dc.identifier.essn | 1550-9109 | es |
| dc.type.hasVersion | info:eu-repo/semantics/acceptedVersion | es |
| dc.subject.unesco | 3325 Tecnología de las Telecomunicaciones | es |
| dc.subject.unesco | 3314 Tecnología Médica | es |